about
Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in ratsEnhancing endogenous stem cells in the newborn via delayed umbilical cord clampingNeurological disorders and the potential role for stem cells as a therapyPermeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapyDietary supplementations as neuroprotective therapies: focus on NT-020 diet benefits in a rat model of strokeUtilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injuryDo bone marrow cells generate neurons?Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental strokeImmediate, but not delayed, microsurgical skull reconstruction exacerbates brain damage in experimental traumatic brain injury modelSpirulina promotes stem cell genesis and protects against LPS induced declines in neural stem cell proliferationBone marrow grafts restore cerebral blood flow and blood brain barrier in stroke rats.Hyperbaric oxygen therapy for treatment of postischemic stroke in adult rats.Hibernation-like state induced by an opioid peptide protects against experimental stroke.Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury.Menstrual blood transplantation for ischemic stroke: Therapeutic mechanisms and practical issues.Combination treatment of hypothermia and mesenchymal stromal cells amplifies neuroprotection in primary rat neurons exposed to hypoxic-ischemic-like injury in vitro: role of the opioid system.NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats.Neural transplantation for treatment of Parkinson's disease.Recent Studies Assessing the Proliferative Capability of a Novel Adult Stem Cell Identified in Menstrual BloodFacilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport.Menstrual blood cells display stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke.Toward personalized cell therapies: autologous menstrual blood cells for stroke.Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!Delta opioid peptide (D-Ala 2, D-Leu 5) enkephalin: linking hibernation and neuroprotection.Transplantation of carotid body cells in the treatment of neurological disorders.Ex vivo gene therapy: transplantation of neurotrophic factor-secreting cells for cerebral ischemia.Gene therapy, cell transplantation and stroke.A role of the choroid plexus in transplantation therapy.Cell transplantation: toward cell therapy.Differential response to ischemia in adjacent hippocampalsectors: neuronal death in CA1 versus neurogenesis in dentate gyrus.Stem cells and neurological diseases.Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke.Mankind's first natural stem cell transplant.Adult stem cell therapy for acute brain injury in children.Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table.Stem cell transplants at childbirth.The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells.Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application.
P50
Q24800152-B2CECF2B-D206-4281-8923-1B66A75C9C00Q26775784-F917A1B5-15E5-4EAB-928E-DD4252E30B26Q26830211-6FEE023D-BC23-40B7-AD5A-945078F28F03Q26865517-AC12E014-8495-478C-AAA8-DD0EDFE6797AQ26991784-C27BB445-F2CC-4F0B-BF95-428BD535414BQ28072473-1E10793C-B3F4-43B6-8DAD-029493D92CFCQ28257495-81D28B7E-0E14-4741-8D6C-D08B0C08CEE2Q28569418-21BBF424-6BE8-4EF6-BDA8-CFF77341964BQ28731270-B1E6A1D3-481D-4EDC-A794-CE52AC55DEB9Q28752354-3096C2C3-629C-4E7F-A690-C168FCB8FF94Q31057511-D4FED3A7-42A9-40C6-9D47-D8446D4BCB39Q33422537-BB18A1A8-735A-42B7-8C90-40F1940C7905Q33469912-C1D86856-60CE-4556-9C94-3E870AC53823Q33508929-AAA08C4B-B2DB-44F0-A183-09929C0EF172Q33816943-A1420264-E76C-4F8B-81DF-5D08A603A436Q34253171-952DB846-DF5D-4CC7-8DD9-34A464B4BE9EQ34450985-EBBB7D55-52D6-4957-BAEC-6DA897BA384BQ34680745-C7C52DC5-F141-4D96-A4E0-574FE75DBCD7Q34731427-DB11B505-44A3-4AA8-8565-530FAF97C6F0Q35040792-F9D7CE38-0650-414B-8CC8-DC2EB1475331Q35130192-DA6640A8-E673-4EA5-9179-1DA4C76EF2E2Q35171618-F7027752-8FAC-4EB0-BAA9-E826EBD23FD1Q35581959-FB08D9D3-A759-46CA-82A9-D80D0148DDA1Q35624272-D7C46D76-52FC-4961-A79D-ECD964DD4364Q35792838-D836C360-ABF8-4AA8-BD34-F84F5836B835Q35880822-F6DCE222-676B-40FB-87BA-75ADC3C18651Q36005428-35730FAF-A6C6-4224-AA4D-49C1CD05F4DCQ36251075-B7DBAEE7-0D6F-4F64-80D1-472D94D199E3Q36251153-0D7DBD20-2789-465A-919B-F0677CAF22C3Q36384687-1C9897F2-6530-49E2-BDE2-5FDBFB52DA95Q36687136-1FCF7A9A-480E-4B34-8F18-45AFC2317A04Q36754266-EAC9C124-1395-4745-804E-247789BF53D9Q37053159-B4F28FD6-4AAC-4716-B5E2-EB798D87821AQ37178107-C56AE13B-0E3F-4FED-8E42-E6435B00A7AAQ37296284-23C85892-31BE-480A-9BEB-67CDFFDC7259Q37320360-ED88742D-B7A0-49C8-987E-19D101E99D42Q37641341-AD24C280-A7F2-4B66-818C-8E600CD8BAA3Q37658508-8EEBF8D2-F648-4374-8F30-180268F2A7CEQ37795969-01F80349-252D-4AE6-8C8C-AA05B00283E4Q37876994-BCF8344B-BEC3-4EE6-BE2F-63FB43A6F20F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cesar V Borlongan
@nl
Cesar V Borlongan
@sl
Cesar V. Borlongan
@en
Cesar V. Borlongan
@es
type
label
Cesar V Borlongan
@nl
Cesar V Borlongan
@sl
Cesar V. Borlongan
@en
Cesar V. Borlongan
@es
altLabel
Cesar Borlongan
@en
prefLabel
Cesar V Borlongan
@nl
Cesar V Borlongan
@sl
Cesar V. Borlongan
@en
Cesar V. Borlongan
@es
P106
P1153
7007115371
P21
P31
P496
0000-0002-2966-9782